Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Cassia Capital Partners LLC

Cassia Capital Partners LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 421 shares of the biopharmaceutical company’s stock after selling 330 shares during the period. Cassia Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Adirondack Trust Co. raised its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the period. Trust Co. of Vermont raised its stake in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares in the last quarter. Nvwm LLC lifted its holdings in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after purchasing an additional 14 shares during the period. Finally, Moss Adams Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 3.6% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 4.5 %

NASDAQ:REGN opened at $697.05 on Wednesday. The business’s fifty day moving average price is $719.16 and its 200 day moving average price is $918.90. The firm has a market capitalization of $76.60 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.86 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REGN. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $983.65.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.